Immix Biopharma Independent Director Acquires 2.6% More Stock [Yahoo! Finance]
Immix Biopharma, Inc. (IMMX)
Company Research
Source: Yahoo! Finance
NASDAQ:IMMX ) recently shelled out US$52k to buy stock, at US$2.23 per share. Although the purchase is not a big one, increasing their shareholding by only 2.6%, it can be interpreted as a good sign. See our latest analysis for Immix Biopharma The Last 12 Months Of Insider Transactions At Immix Biopharma In fact, the recent purchase by Independent Director Jason Hsu was not their only acquisition of Immix Biopharma shares this year. They previously made an even bigger purchase of US$267k worth of shares at a price of US$4.88 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$2.22). Their view may have changed since then, but at least it shows they felt optimistic at the time. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value
Show less
Read more
Impact Snapshot
Event Time:
IMMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMMX alerts
High impacting Immix Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
IMMX
News
- Immix Biopharma, Inc. (NASDAQ: IMMX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 [Yahoo! Finance]Yahoo! Finance
- Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2GlobeNewswire
- Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board [Yahoo! Finance]Yahoo! Finance
- Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory BoardGlobeNewswire
IMMX
Analyst Actions
- 10/3/24 - HC Wainwright
IMMX
Sec Filings
- 11/12/24 - Form 10-Q
- 8/26/24 - Form 4
- IMMX's page on the SEC website